Analyst Consensus ?
1 unmapped firm rating excluded from the percentages.
Akamai Technologies, Inc. · AKAM · FY2026 Q1 · Calendar Q2 2026
Akamai's Q1 2026 results mark an inflection point in its cloud infrastructure strategy. The company secured a landmark seven-year, $1.8 billion AI infrastructure contract—the largest in its history—while Cloud Infrastructure Services (CIS) revenue surged 40% year over year and security revenue grew 11%. Management raised guidance and signaled double-digit revenue growth for 2027, supported by an aggressive GPU deployment plan with NVIDIA across 4,300 points of presence. The trade-off is a sharp increase in capital expenditure, projected at 40–42% of revenue for the full year, which pressures near-term free cash flow even as it builds the platform for long-term AI-driven growth.
Akamai Technologies, Inc. (AKAM) is a leading global provider of cloud services, specializing in the secure delivery, optimization, and protection of online content and business applications across the internet. The company's primary focus involves offering sophisticated cloud-based solutions designed to shield digital infrastructure, websites, applications (including APIs), and end-users from a wide array of cyberattacks and online threats, all while simultaneously enhancing performance. Akamai further excels in accelerating web and mobile experiences, facilitating dynamic and highly responsive websites and applications.…
1 unmapped firm rating excluded from the percentages.
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 27, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | May 14, 2026 |
| B of A Securities | Buy | Neutral | Upgrade | May 13, 2026 |
| Susquehanna | Positive | Positive | Maintain | May 11, 2026 |
| UBS | Neutral | Neutral | Maintain | May 8, 2026 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | May 8, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | May 8, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | May 8, 2026 |
| Keybanc | Overweight | Overweight | Maintain | May 8, 2026 |
| Guggenheim | Buy | Buy | Maintain | May 8, 2026 |
| Baird | Neutral | Outperform | Downgrade | Apr 2, 2026 |
| TD Cowen | Hold | Hold | Maintain | Feb 20, 2026 |
| DA Davidson | Buy | Buy | Maintain | Feb 13, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Jan 16, 2026 |
| Raymond James | Outperform | Outperform | Maintain | Aug 8, 2025 |
| Needham | Hold | Hold | Maintain | Feb 21, 2025 |
| JP Morgan | Underweight | Underweight | Maintain | Feb 21, 2025 |
| Oppenheimer | Outperform | Perform | Upgrade | Dec 2, 2024 |
| Tigress Financial | Strong Buy | Strong Buy | Maintain | Aug 29, 2024 |
| Craig-Hallum | Buy | Hold | Upgrade | Aug 9, 2024 |
| HSBC | Hold | Reduce | Upgrade | Jul 24, 2024 |
| CFRA | Hold | Hold | Maintain | May 24, 2023 |
| Loop Capital | Hold | Hold | Maintain | Mar 1, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 15, 2023 |
| Truist Securities | Buy | Buy | Maintain | Aug 10, 2022 |
| FBN Securities | Outperform | Outperform | Maintain | Aug 10, 2022 |
| Credit Suisse | Neutral | Neutral | Maintain | Feb 10, 2021 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Jul 29, 2020 |
| B. Riley Securities | Buy | Buy | Maintain | Apr 29, 2020 |
| B. Riley FBR | Buy | Buy | Maintain | Apr 29, 2020 |
| Nomura Instinet | Neutral | Neutral | Maintain | Apr 15, 2020 |
| Nomura | Neutral | Neutral | Maintain | Apr 15, 2020 |
| Goldman Sachs | Neutral | Sell | Upgrade | Mar 26, 2020 |
| B. Riley | Buy | Buy | Maintain | Feb 12, 2020 |
| Deutsche Bank | Sell | Hold | Downgrade | Mar 25, 2019 |
| MKM Partners | Buy | Buy | Maintain | Jun 27, 2018 |
| Wells Fargo | Market Perform | Market Perform | Maintain | Oct 25, 2017 |
| Drexel Hamilton | Buy | Buy | Maintain | Mar 21, 2017 |
| FBR Capital | Market Perform | Underperform | Upgrade | Oct 26, 2016 |
| Pacific Crest | Overweight | Downgrade | Jul 27, 2016 | |
| Stifel Nicolaus | Hold | Hold | Maintain | Mar 24, 2016 |
| Macquarie | Neutral | Neutral | Maintain | Nov 3, 2015 |
| Canaccord Genuity | Hold | Hold | Maintain | Oct 28, 2015 |
| JMP Securities | Market Outperform | Market Perform | Upgrade | Aug 28, 2015 |
| Jefferies | Hold | Hold | Maintain | May 2, 2014 |
| Maxim Group | Buy | Buy | Maintain | Mar 15, 2013 |
| Janney Montgomery Scott | Neutral | Buy | Downgrade | Feb 7, 2013 |
| Janney Capital | Neutral | Buy | Downgrade | Feb 7, 2013 |
| Oxen Group | Hold | Hold | Maintain | Mar 14, 2012 |
| Stifel | Buy | Buy | Maintain | Feb 9, 2012 |
| PiperJaffray | Neutral | Neutral | Maintain | Feb 9, 2012 |
Upside is calculated against the persisted previous close $113.75. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Roger Boyd | $125 | $111.79 | +9.9% | Jul 29, 2026 |
| Evercore ISI | Peter Levine | $175 | $113.3 | +53.8% | Jul 27, 2026 |
| Morgan Stanley | Sanjit Singh | $165 | $161.14 | +45.1% | May 14, 2026 |
| Susquehanna | Shyam Patil | $175 | $147.71 | +53.8% | May 11, 2026 |
| Scotiabank | Patrick Colville | $180 | $141.92 | +58.2% | May 8, 2026 |
| UBS | Analyst unavailable | $160 | $141.46 | +40.7% | May 8, 2026 |
| Robert W. Baird | Analyst unavailable | $150 | $140.3 | +31.9% | May 8, 2026 |
| Oppenheimer | Analyst unavailable | $180 | $140.73 | +58.2% | May 8, 2026 |
| D.A. Davidson | Analyst unavailable | $185 | $135.3 | +62.6% | May 8, 2026 |
| Raymond James | Analyst unavailable | $140 | $135.93 | +23.1% | May 8, 2026 |
| Evercore ISI | Analyst unavailable | $165 | $133.5 | +45.1% | May 8, 2026 |
| Craig-Hallum | Analyst unavailable | $190 | $116.69 | +67.0% | May 8, 2026 |
| KeyBanc | Jackson Ader | $195 | $116.69 | +71.4% | May 8, 2026 |
| Raymond James | Frank Louthan | $120 | $105.47 | +5.5% | Mar 12, 2026 |
| Raymond James | Frank Louthan | $100 | $99.02 | -12.1% | Feb 23, 2026 |
| Goldman Sachs | Analyst unavailable | $76 | $94.17 | -33.2% | Feb 23, 2026 |
| Piper Sandler | Analyst unavailable | $97 | $94.17 | -14.7% | Feb 23, 2026 |
| Scotiabank | Patrick Colville | $120 | $99.42 | +5.5% | Feb 20, 2026 |
| Susquehanna | Analyst unavailable | $120 | $98.89 | +5.5% | Feb 20, 2026 |
| Evercore ISI | Analyst unavailable | $115 | $99.26 | +1.1% | Feb 20, 2026 |
| Robert W. Baird | Analyst unavailable | $110 | $109.59 | -3.3% | Feb 20, 2026 |
| UBS | Roger Boyd | $110 | $109.59 | -3.3% | Feb 20, 2026 |
| KeyBanc | Analyst unavailable | $120 | $109.59 | +5.5% | Feb 20, 2026 |
| Morgan Stanley | Sanjit Singh | $120 | $109.59 | +5.5% | Feb 20, 2026 |
| Oppenheimer | Analyst unavailable | $115 | $92.68 | +1.1% | Feb 5, 2026 |
| Morgan Stanley | Analyst unavailable | $115 | $88.12 | +1.1% | Jan 12, 2026 |
| Scotiabank | Analyst unavailable | $105 | $87.36 | -7.7% | Jan 9, 2026 |
| Piper Sandler | James Fish | $89 | $85.1 | -21.8% | Jan 5, 2026 |
| KeyBanc | Jackson Ader | $115 | $85.89 | +1.1% | Dec 15, 2025 |
| Oppenheimer | Analyst unavailable | $100 | $87.17 | -12.1% | Nov 17, 2025 |
| Piper Sandler | James Fish | $83 | $70.53 | -27.0% | Aug 8, 2025 |
| Morgan Stanley | Analyst unavailable | $85 | $73.65 | -25.3% | Aug 5, 2025 |
| Morgan Stanley | Keith Weiss | $90 | $73.81 | -20.9% | Apr 16, 2025 |
| Robert W. Baird | William Power | $115 | $101.02 | +1.1% | Nov 11, 2024 |
| HSBC | Stephen Bersey | $121 | $101.02 | +6.4% | Nov 11, 2024 |
| Scotiabank | Patrick Colville | $115 | $91.57 | +1.1% | Aug 9, 2024 |
| Craig-Hallum | Jeff Van Rhee | $125 | $91.57 | +9.9% | Aug 9, 2024 |
| RBC Capital | Mark Mahaney | $100 | $91.57 | -12.1% | Aug 9, 2024 |
| Guggenheim | Raymond McDonough | $128 | $96.97 | +12.5% | Jul 29, 2024 |
| HSBC | Stephen Bersey | $96 | $96.37 | -15.6% | Jul 24, 2024 |
| Piper Sandler | James Fish | $112 | $95.14 | -1.5% | Jul 15, 2024 |
| Scotiabank | Patrick Colville | $110 | $92.22 | -3.3% | Jul 8, 2024 |
| Susquehanna | Shyam Patil | $135 | $92.86 | +18.7% | May 10, 2024 |
| Piper Sandler | James Fish | $114 | $94.39 | +0.2% | May 10, 2024 |
| KeyBanc | Thomas Blakey | $119 | $94.48 | +4.6% | May 10, 2024 |
| D.A. Davidson | Rudy Kessinger | $125 | $101.44 | +9.9% | May 7, 2024 |
| Piper Sandler | James Fish | $136 | $105.82 | +19.6% | Apr 9, 2024 |
| Robert W. Baird | William Power | $135 | $110.16 | +18.7% | Mar 7, 2024 |
| Guggenheim | Ramond McDonnough | $75 | $78.66 | -34.1% | Feb 16, 2023 |
| Loop Capital Markets | Analyst unavailable | $91 | $87.49 | -20.0% | Feb 7, 2023 |
| Morgan Stanley | Keith Weiss | $102 | $95.81 | -10.3% | Aug 10, 2022 |
| Truist Financial | Analyst unavailable | $125 | $95.98 | +9.9% | Aug 10, 2022 |
| Morgan Stanley | Analyst unavailable | $102 | $92.26 | -10.3% | Aug 10, 2022 |
| RBC Capital | Analyst unavailable | $110 | $95.08 | -3.3% | Aug 10, 2022 |
| Morgan Stanley | Analyst unavailable | $110 | $90.65 | -3.3% | Jul 11, 2022 |
| Piper Sandler | Analyst unavailable | $102 | $93.13 | -10.3% | Jul 6, 2022 |
| Morgan Stanley | Analyst unavailable | $118 | $100.74 | +3.7% | May 4, 2022 |
| Piper Sandler | James Fish | $126 | $116.7 | +10.8% | Apr 25, 2022 |
| Tigress Financial | Ivan Feinseth | $168 | $109.94 | +47.7% | Jan 26, 2022 |
| KeyBanc | Thomas Blakey | $140 | $112.08 | +23.1% | Jan 18, 2022 |
| Morgan Stanley | Keith Weiss | $130 | $110.87 | +14.3% | Nov 3, 2021 |
| Truist Financial | Gregory P Miller | $140 | $105.13 | +23.1% | Nov 2, 2021 |
Track every rating change on AKAM the moment it posts. Free to start.
Start freeFollow AKAM with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeRevenue rose 6% YoY to $1.074 billion, narrowly topping the $1.073 billion consensus, and EPS of $1.61 edged the $1.60 estimate. The stock surged 25.8% on the announcement—26.6% versus a flat SPY benchmark—on volume four times the baseline, before drifting back 3.9% in subsequent sessions. The standout development was the $1.8 billion multi-year AI deal, which shifts Akamai's growth narrative from steady mid-single-digit revenue expansion to a potential double-digit trajectory by 2027. CapEx guidance stepped up meaningfully, with Q2 targeted at $433–$453 million and full-year spending at roughly 40–42% of revenue.
Management raised full-year guidance, citing the CIS pipeline and the $1.8 billion deal as underpinning double-digit revenue growth into 2027. CapEx is projected at $433–$453 million for Q2 and approximately 40–42% of total revenue for the full year—a material step-up from prior spending levels. Non-GAAP operating margin is expected to hold around 26%. The company continues aggressive share repurchases and remains opportunistic on M&A.
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.